Long-term safety and tolerability of remibrutinib (LOU064) in Phase 2b study in chronic spontaneous urticaria patients

Authors
Category Primary study
ConferenceAllergy: European Journal of Allergy and Clinical Immunology
Year 2023
This article has no abstract
Epistemonikos ID: 3d57ef2d88ea2b4c6710ede87b1b2312000a8493
First added on: Apr 30, 2026